Arbor announced the launch of Nymalize (nimodipine) Oral Solution in a new 10mL (30mg) unit dose cup formulation. This new option is intended for patients who need a dosage lower than the standard 20mL (60mg) dose.

Nymalize Oral Solution was approved in 2013 for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (ie, Hunt and Hess Grades I–V). It is the only ready-to-use oral solution of nimodipine and is intended for patients who cannot swallow capsules. 

Related Articles

Nimodipine, a dihydropyridine calcium channel blocker (CCB), inhibits calcium ion transfer into muscle cells and thus inhibits contractions of vascular smooth muscle. Nimodipine demonstrated a greater effect on cerebral arteries than on arteries elsewhere in the body. 

Nymalize is available as 473mL (16oz) bottles and as a carton of 12 individually wrapped 10mL or 20mL unit dose cups. 

For more information call (866) 516-4950 or visit